T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy jamanetwork.com/journals/jamao…

BREAKING: The #FDA now requires a boxed warning for T-cell malignancies on BCMA- or CD19-directed CAR T-cell therapies.

targetedonc.com/view/fda-calls…

Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK - British Journal of Anaesthesia bjanaesthesia.org/article/S0007-…

Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives frontiersin.org/journals/immun…

Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma | Cellular Oncology link.springer.com/article/10.100…

The role of immune reconstitution in relapse after allogeneic hematopoietic stem cell transplantation: Expert Review of Clinical Immunology: Vol 20 , No 5 - Get Access tandfonline.com/doi/full/10.10…

The new era of immunological treatment, last updated and future consid... sciencedirect.com/science/articl…

CAR’TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment: Molecular Therapy Oncology cell.com/molecular-ther…

CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy | Cancer Gene Therapy nature.com/articles/s4141…

A safety and efficacy study of allogeneic HSCT for refractory and relapsed T-cell ALL/LBL patients who achieved complete remission after autologous CD7 CAR-T Rx
onlinelibrary.wiley.com/doi/10.1111/bj…

Christian Chabannon Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx The EBMT Ibrahim Yakoub-Agha Mahmoud Aljurf World Health Organization (WHO) Thanks for sharing Christian Chabannon …credit of table to Josu Iraola Truchuelo , adapted from LinkedIn linkedin.com/posts/josu-ira…

ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy
#cellular_therapy
#CART
#Myeloma sciencedirect.com/science/articl…

Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme | Blood Cancer Journal nature.com/articles/s4140…

Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia | Cancer Immunology, Immunotherapy
#cellular_therapy
#CART link.springer.com/article/10.100…

Dr Syed Osman Ahmed showing the disparities in access to #CART Cells across the globe during the joint #WBMT The EBMT session at #EBMT2024 Ibrahim Yakoub-Agha Mahmoud Aljurf World Health Organization (WHO)

Roberto Mina presents the HRQOL results of CARTITUDE-4 in patients with lenalidomide-refractory MM who had 1-3 prior lines of therapy who were treated with ciltacel vs SOC #mmsm
Generalised improvements and label extended in this setting

The number of long-term survivors of #HCT and #celltherapy is rapidly expanding. This webinar will review the 2023 updated guidelines for pediatric & adult survivorship, while highlighting the changes to the guidelines from 2012. Register now: ow.ly/yGk050RhwQW

AML with myelodysplasia-related genetics can be combined as a single group encompassing MR-defining gene mutations and cytogenetics. ow.ly/IJVx50RbKgI #myeloidneoplasia #healthservicesandoutcomes

Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical- Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy astctjournal.org/article/S2666-…

Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical- Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy astctjournal.org/article/S2666-…